Company Description
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain.
Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression.
The company has a partnership with Alvogen and Lotus to develop and commercialize NRX-101 for the suicidal bipolar depression treatment, as well as an agreement with Nephron Pharmaceuticals, Inc. to develop ketamine.
The company was founded in 2015 and is based in Wilmington, Delaware.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Stephen H. Willard Esq. |
Contact Details
Address: 1201 Orange Street, Suite 600 Wilmington, Delaware 19801 United States | |
| Phone | 484-254-6134 |
| Website | nrxpharma.com |
Stock Details
| Ticker Symbol | NRXP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001719406 |
| CUSIP Number | 089482103 |
| ISIN Number | US6294441000 |
| Employer ID | 82-2844431 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jonathan C. Javitt M.D., M.P.H. | Co-Founder, Chief Scientist Officer and Chairman |
| Stephen H. Willard Esq. | Acting Corporate Secretary, Chief Executive Officer and Director |
| Dr. Riccardo Panicucci Ph.D. | Chief Technology Officer |
| Dr. Seth L. Van Voorhees Ph.D. | Treasurer |
| Richard Clavano Narido | Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Suzanne Messere | Investor Relations |
| Dr. Philip T. Lavin Ph.D. | Chief Methodologist |
| Dr. Dennis K. McBride Ph.D. | Chief Strategy Officer and Senior Scientist |
| Matthew Patrick Duffy | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | 424B5 | Filing |
| Apr 15, 2024 | 8-K | Current Report |
| Apr 15, 2024 | 424B3 | Prospectus |
| Apr 15, 2024 | 424B3 | Prospectus |
| Apr 2, 2024 | 8-K | Current Report |
| Mar 29, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 20, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |